Stock Traders Purchase Large Volume of Humacyte Put Options (NASDAQ:HUMA)

Humacyte, Inc. (NASDAQ:HUMA) was the target of some unusual options trading on Friday. Investors bought 6,057 put options on the stock. This is an increase of approximately 114% compared to the average daily volume of 2,835 put options.

Institutional Trading of Humacyte

A number of institutional investors have recently made changes to their positions in the stock. Lazari Capital Management Inc. bought a new stake in shares of Humacyte in the second quarter worth approximately $27,000. Truist Financial Corp purchased a new stake in Humacyte in the third quarter worth approximately $28,000. Prudential Financial Inc. purchased a new stake in Humacyte in the second quarter worth approximately $28,000. Financial Advisors Network Inc. bought a new stake in Humacyte in the 2nd quarter worth approximately $28,000. Finally, Equitable Holdings Inc. purchased a new stake in Humacyte during the 3rd quarter valued at $29,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Humacyte Stock Up 5.8%

Shares of HUMA stock traded up $0.07 during mid-day trading on Friday, hitting $1.19. The company’s stock had a trading volume of 1,626,164 shares, compared to its average volume of 4,331,483. The stock has a market cap of $187.67 million, a price-to-earnings ratio of -5.11 and a beta of 1.88. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.90 and a current ratio of 1.62. Humacyte has a 52-week low of $1.09 and a 52-week high of $6.77. The business has a 50-day moving average price of $1.60 and a 200 day moving average price of $1.93.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.03. The business had revenue of $0.75 million for the quarter, compared to analysts’ expectations of $0.92 million. Research analysts predict that Humacyte will post -1.27 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently weighed in on HUMA. Benchmark cut their price target on Humacyte from $14.00 to $11.00 and set a “buy” rating on the stock in a research note on Thursday, November 13th. UBS Group set a $6.00 target price on Humacyte in a research note on Monday, October 13th. TD Cowen lowered their price target on Humacyte from $5.00 to $3.50 and set a “buy” rating for the company in a research report on Tuesday, August 12th. HC Wainwright dropped their price target on shares of Humacyte from $4.00 to $3.00 and set a “buy” rating on the stock in a research note on Tuesday, August 12th. Finally, Wall Street Zen lowered shares of Humacyte from a “hold” rating to a “sell” rating in a research note on Sunday, August 17th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Humacyte has an average rating of “Moderate Buy” and a consensus price target of $8.29.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.